SAN DIEGO, CA--(Marketwire - September 08, 2008) - Aegis Therapeutics, a drug delivery technology licensing company and leader in transmucosal drug delivery, will present a talk entitled: “Non-Invasive Peptide Delivery, Reformulation, and the Pharma Finance Environment” at the GTCbio “4th Modern Drug Discovery & Development Summit.” The conference will be held on October 15-17, 2008, at the Hilton La Jolla Torrey Pines, San Diego, CA. Dr. Edward T. Maggio, President and CEO of Aegis, will address key issues in peptide reformulation such as achieving adequate non-invasive bioavailability, preventing peptide aggregation, and minimizing immunogenicity, as well as opportunities and benefits of reformulation of peptide drugs amenable to 505(b)2 FDA regulatory treatment such as minimized business, regulatory, and clinical risks; expanded clinical indications; greater patient acceptance; increased product sales, and maximizing value extraction from an existing product franchise.
